Table 4 α-NETA and analogs 27 and 6 suppress clinical EAE.

From: Novel CMKLR1 Inhibitors for Application in Demyelinating Disease

Treatment Group

AUC (Mean ± SEM)

Day of onset (Mean ± SEM)

Maximum Score (Mean ± SEM)

Incidence of hind limb paralysis

Vehicle

44.7 ± 5.5

12.5 ± 0.7

2.9 ± 0.1

7/8 (87.5%)

α-NETA

31.9 ± 4.0*

14.4 ± 0.6*

2.6 ± 0.2

5/8 (62.5%)

27

24.3 ± 4.2*

16.0 ± 0.9*

2.1 ± 0.1

1/8 (12.5%)§

6

25.2 ± 4.0*

14.5 ± 0.4*

2.4 ± 0.2

3/8 (37.5%)

  1. EAE was induced in WT C57/BL6 mice by active immunization with MOG35–55/CFA/PTX and monitored daily for clinical signs as previously described. Mice were treated with α-NETA, 6, 27 (10 mg/kg), or vehicle (10% captisol) daily, beginning at the time of disease induction and ending on D21. n = 8 mice per group. AUC = area under the curve, calculated for each individual mouse as mean clinical score x day.
  2. *p < 0.05, as determined one-way ANOVA compared to vehicle.
  3. p < 0.05 as determined by t-test compared to α-NETA.
  4. §p < 0.05 as determined by Chi-square (2 × 2 contingency table) test compared to α-NETA.
Back to article page